Serum nitric oxide synthase activity is a novel predictor of impaired vasorelaxation in rats
Staff Page Link
Cholesterol, Diagnostic, Nitric oxide synthase, Serum, Vasorelaxation
1. It is well documented that both acetylcholine (ACh)-evoked arterial relaxation and brachial artery flow-mediated vasodilatation are blunted in hypercholesterolaemic patients. However, there are no simple diagnostic methods to detect the pathology of blood vessels of patients.
2. To establish the use of serum nitric oxide synthase (NOS) activity as a diagnostic parameter for impaired vasorelaxation, animals with different levels of vascular healthiness were made by feeding Sprague–Dawley rats a normal diet, a high-cholesterol diet (HCD) or an HCD supplemented with 10 mg/kg per day, p.o., simvastatin, a cholesterol-lowering drug, for 30 days. Serum total cholesterol levels, serum NOS activity and ACh-induced vasorelaxation of the isolated aorta were determined at the end of the experiment.
3. Consumption of HCD for 30 days resulted in an increase in serum total cholesterol, attenuated ACh-induced nitric oxide/endothelium-dependent aortic relaxation and decreased NOS activity. Concomitant administration of simvastatin lowered the elevated blood cholesterol levels with complete reversal of the attenuated ACh-induced aortic relaxation and serum NOS activity. An attempt was made to correlate serum NOS activity and the magnitude of ACh-elicited vascular relaxation among the different groups. A positive correlation (r = 0.8329; P < 0.001; n = 30) was found between serum NOS activity and vascular relaxation.
4. This finding is a good foundation for the development of a simple and low-cost alternative for diagnosing vascular diseases and evaluating the effectiveness of drugs on the vascular system in patients.
Clinical and Experimental Pharmacology and Physiology
Chan, E.,Chan, J.,Wu, J.,Wan, C.,Leung, G.,Lee, S.,Kwan, Y.,& Chan, S. (2012). Serum nitric oxide synthase activity is a novel predictor of impaired vasorelaxation in rats. Clinical and Experimental Pharmacology and Physiology, 39 (10), 894-896. http://dx.doi.org/10.1111/j.1440-1681.2012.05748.x